GlassScriptPhysician profile
Robert A Azurin
NPI 1700149663
$11,873.04
in general payments reported to CMS, 2019-2025
38 companies · $965 in 2025
The $965 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,517 · 2020: $1,847 · 2021: $2,398 · 2022: $1,652 · 2023: $1,457 · 2024: $1,037 · 2025: $965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,459.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,311.07 | 2019-2025 | |
| Novo Nordisk INC | $1,098.07 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,063.98 | 2019-2024 | Jardiance |
| Abbvie INC. | $1,023.89 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $990.25 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $743.57 | 2019-2024 | Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $693.74 | 2021-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $663.10 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Sanofi-Aventis U.S. LLC | $630.88 | 2019-2025 | |
| Amgen INC. | $561.43 | 2019-2025 | Evenity, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $395.05 | 2019-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $368.83 | 2019-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $318.78 | 2019-2020 | |
| Allergan, INC. | $286.65 | 2019-2020 | |
| Mannkind Corporation | $276.59 | 2019-2020 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Azurin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.